Manifestation of Subclinical Extrapulmonary Tuberculosis after COVID-19 Vaccination as Supraclavicular Lymphadenopathy

Abstract

Lymphadenopathy after coronavirus disease 2019 (COVID-19) vaccination is a common side effect that usually resolves within several days to weeks, and only observation is recommended. However, for prolonged lymphadenopathy, other possibilities, including malignancy or other lymphoproliferative diseases, may be considered. Herein, we report the case of a 66-year-old woman who experienced prolonged ipsilateral supraclavicular lymph node enlargement after the second dose of the ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccine, which was eventually diagnosed as extrapulmonary tuberculosis.

Tuberculous dactylitis of the toe in an immunocompetent young man: a case report and review of literature

“…The administration of the COVID-19 vaccine has been implicated in the development of subclinical tuberculosis. 5 COVID-19 vaccines may elicit innate immunity via intrinsic adjuvant activity and induce the production of type I interferon against SARS-CoV-2. This may cause the immune response to be skewed toward antiviral responses and weaken antituberculosis immunity.…”